TAS 121

Drug Profile

TAS 121

Alternative Names: TAS-121

Latest Information Update: 14 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Taiho Pharmaceutical
  • Class Antineoplastics
  • Mechanism of Action Epidermal growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Non-small cell lung cancer

Most Recent Events

  • 08 Sep 2017 Efficacy, safety and pharmacokinetics data from a phase I trial in Non-small cell lung cancer presented at the 42nd European Society for Medical Oncology Congress (ESMO-2017)
  • 08 Sep 2017 Taiho Pharmaceutical completes a phase I trial in Non-small cell lung cancer (Late-stage disease, Second-line therapy or greater) in Japan before September 2017 (JapicCTI-142651)
  • 30 Sep 2014 Phase-I clinical trials in Non-small cell lung cancer (Late-stage disease, Second-line therapy or greater) in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top